Bio-Rad Laboratories (NYSE:BIO) executives said the company finished 2025 within revised guidance for revenue and operating ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended ...

During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its projected EPS growth exceeds 115%. Thursday’s results will test whether that ...

Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

The earnings results for Bio-Rad Laboratories (NYSE: BIO) for Q4 were made public on Thursday, February 12, 2026 at 04:15 PM. Here's a comprehensive overview of the announcement. Bio-Rad Laboratories ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...